Prevention of cisplatin-induced delayed emesis: Still unsatisfactory

Supportive Care in Cancer

Volumn 8, Issue 3, 2000, Pages 229-232

  Roila, F ^a  

^a Policlinico Hospital   (Italy)

Author keywords

Antiemetics; Cisplatin; Delayed emesis

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; METOCLOPRAMIDE; ONDANSETRON;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG EFFICACY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; VOMITING;

EID: 0343294008     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050290     Document Type: Article

References (5)

1. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (1998) Prevention of chemotherapy-and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9:811-819
2. Hesketh PJ, Gralla RJ, Webb RT, et al (1999) Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 17:338-343
3. Italian Group for Antiemetic Research (1994) Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Ann Oncol 5:585-589
4. Italian Group for Antiemetic Research (1998) Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 16:2937-2942
5. Navari RM, Rick RR, Reinhardt MD. et al (1999) Reduction of cisplatin-induced emesis by a selective neurokin-in-1-receptor antagonist. N Engl J Med 340:190-195